Ionis PharmaceuticalsLTS:0JDI +2.08%62 Current Ratio is 4.10 as of Mar. 2026, which is 46% below its 10-year median of 7.62. GuruFocus rates LTS:0JDI with a GF Score™ of 62/100 and a GF Value™ of $53.57 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,412 Biotechnology companies, Ionis Pharmaceuticals ranks better than 51.2% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ionis Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 4.10.
Ionis Pharmaceuticals has a current ratio of 4.10. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Ionis Pharmaceuticals's Current Ratio or its related term are showing as below:
LTS:0JDI'
s Current Ratio Range Over the Past 10 Years
Min: 2.79 Med: 7.62 Max: 10.94
Current: 4.1
During the past 13 years, Ionis Pharmaceuticals's highest Current Ratio was 10.94. The lowest was 2.79. And the median was 7.62.
LTS:0JDI's Current Ratio is ranked better than 51.2% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs LTS:0JDI: 4.10
Ionis Pharmaceuticals (LTS:0JDI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Ionis Pharmaceuticals Current Ratio Related Terms
Ionis Pharmaceuticals Current Ratio Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JDI vs EXEL, BBIO, AXSM: Current Ratio Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (LTS:0JDI) has a Current Ratio of 4.10 as of Mar. 2026. This is 46% below median its historical median of 7.62. Over the past decade, Ionis Pharmaceuticals' Current Ratio has ranged from 2.79 to 10.94. According to the industry distribution chart, Ionis Pharmaceuticals ranks #689 out of 1412 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Ionis Pharmaceuticals' Current Ratio too high?
Ionis Pharmaceuticals' current Current Ratio of 4.10 is 46% below median its 10-year median of 7.62. Over the past 10 years, this metric has ranged from a low of 2.79 to a high of 10.94. The Biotechnology industry median Current Ratio is 3.89. Ionis Pharmaceuticals' value of 4.10 is 5.4% above this industry median. Based on the distribution chart, Ionis Pharmaceuticals ranks #689 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Current Ratio compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #689 out of 1412 companies for Current Ratio. This puts Ionis Pharmaceuticals in the upper half of its industry. The industry median Current Ratio is 3.89. Ionis Pharmaceuticals' value of 4.10 is 5.4% above this benchmark. Historically, Ionis Pharmaceuticals' own Current Ratio has ranged from 2.79 to 10.94 over the past decade. While the company's 10-year median is 7.62 vs. the industry median of 3.89, Ionis Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ionis Pharmaceuticals's current Current Ratio of 4.10 is 5.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current Current Ratio is 4.10, which is 46% below median its own 10-year median of 7.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.57, compared to a current price of $80.36 — trading 50% above its estimated fair value. The current Current Ratio is 4.10, which is 46% below median its 10-year median of 7.62 and 5.4% above the Biotechnology industry median of 3.89. Ionis Pharmaceuticals' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Current Ratio is 4.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of $80.36 is trading 50% above its estimated GF Value™ of $53.57.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for LTS:0JDI:
Current Ratio: 4.10 (46% below median its 10-year median of 7.62)
GF Value™: $53.57 vs. price of $80.36 (50% above fair value)
Industry Position: 5.4% above the Biotechnology median (#689 of 1412)
No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
62GF Score
Get the complete analysis for LTS:0JDI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDI has been successfully added to your 
